A detailed history of Royal Bank Of Canada transactions in Humacyte, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 8,651 shares of HUMA stock, worth $29,932. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,651
Previous 51,723 83.27%
Holding current value
$29,932
Previous $248,000 81.05%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.11 - $9.46 $220,097 - $407,461
-43,072 Reduced 83.27%
8,651 $47,000
Q2 2024

Aug 14, 2024

SELL
$2.87 - $9.1 $20,689 - $65,601
-7,209 Reduced 12.23%
51,723 $248,000
Q1 2024

Nov 05, 2024

BUY
$2.57 - $4.84 $18,527 - $34,891
7,209 Added 13.94%
58,932 $183,000
Q1 2024

May 15, 2024

BUY
$2.57 - $4.84 $96,336 - $181,427
37,485 Added 174.78%
58,932 $183,000
Q4 2023

Feb 14, 2024

BUY
$1.99 - $3.12 $22,781 - $35,717
11,448 Added 114.49%
21,447 $60,000
Q3 2023

Nov 14, 2023

BUY
$2.75 - $4.48 $15,163 - $24,702
5,514 Added 122.94%
9,999 $29,000
Q2 2023

Aug 14, 2023

BUY
$2.86 - $4.97 $1,224 - $2,127
428 Added 10.55%
4,485 $12,000
Q1 2023

May 15, 2023

SELL
$2.11 - $3.25 $10,041 - $15,466
-4,759 Reduced 53.98%
4,057 $12,000
Q4 2022

Feb 14, 2023

BUY
$2.02 - $3.62 $17,353 - $31,099
8,591 Added 3818.22%
8,816 $18,000
Q3 2022

Nov 14, 2022

BUY
$1.22 - $5.14 $153 - $647
126 Added 127.27%
225 $1,000
Q2 2022

Aug 15, 2022

SELL
$3.21 - $7.86 $7,537 - $18,455
-2,348 Reduced 95.95%
99 $0
Q1 2022

May 16, 2022

BUY
$4.65 - $7.4 $11,127 - $17,708
2,393 Added 4431.48%
2,447 $17,000
Q4 2021

Feb 14, 2022

BUY
$7.25 - $11.6 $391 - $626
54 New
54 $0

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $356M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.